This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	MicroRNA-106a (miRNA-106a); early growth response 1 (EGR1); specificity protein 1 transcription factor (SP1); IL-10	Studies in cell culture suggest that miRNA-106a, EGR1 and SP1 could be targets to treat inflammatory diseases. In cell culture, miRNA-106a downregulated production of the anti-inflammatory cytokine IL-10. Additional computational and *in vitro* studies showed that EGR1 and SP1 regulated miRNA-106a transcription, resulting in a decrease in IL-10 expression. Ongoing studies are evaluating the role of these regulatory mechanisms in inflammatory diseases. ActoGeniX N.V.'s AG011, a formulation of *Lactococcus lactis* engineered to secrete human IL-10, is in a Phase I/II trial to treat ulcerative colitis (UC). ***SciBX* 2(13); doi:10.1038/scibx.2009.543** **Published online April 2, 2009**	Unpatented; unlicensed	Sharma, A. *et al. Proc. Natl. Acad. Sci. USA*; published online March 23, 2009; doi:10.1073/pnas.0808743106 **Contact:** Balaram Ghosh, Institute of Genomics and Integrative Biology, Delhi, India e-mail: bghosh@igib.res.in